A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.

Authors

Virginia F. Borges

University of Colorado Cancer Center, Aurora, CO

Virginia F. Borges , Arlene Chan , Nancy U. Lin , Margaret Eleanor Tonda , Mark Shilkrut , Carlos A. Alemany

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results.

First Author: Aditya Bardia

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.

First Author: Kevin Kalinsky

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid biopsy.

First Author: Jing Shan Lim

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).

First Author: Erika Paige Hamilton